Høhloch, Karin

[["dc.bibliographiccitation.journal","Annals of Oncology"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Lakhani, Vijai J."],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Jung, Werner"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T11:14:10Z"],["dc.date.available","2018-11-07T11:14:10Z"],["dc.date.issued","2008"],["dc.format.extent","184"],["dc.identifier.isi","000256693500359"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54064"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.publisher.place","Oxford"],["dc.relation.conference","10th International Conference on Malignant Lymphoma"],["dc.relation.eventlocation","Lugano, SWITZERLAND"],["dc.relation.issn","0923-7534"],["dc.title","Tandem HD-chemotherapy and myeloablative radioimmunotherapy with 131I-anti-CD20 rituximab in relapsed and refractory B-cell lymphoma: Final results of a phase II study of the German Rait Study Group"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","236"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","British Journal of Haematology"],["dc.bibliographiccitation.lastpage","245"],["dc.bibliographiccitation.volume","180"],["dc.contributor.author","Hohloch, K."],["dc.contributor.author","Altmann, B."],["dc.contributor.author","Pfreundschuh, M."],["dc.contributor.author","Loeffler, M."],["dc.contributor.author","Schmitz, N."],["dc.contributor.author","Zettl, F."],["dc.contributor.author","Ziepert, M."],["dc.contributor.author","Trümper, L."],["dc.date.accessioned","2021-06-01T10:47:11Z"],["dc.date.available","2021-06-01T10:47:11Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1111/bjh.15029"],["dc.identifier.issn","0007-1048"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85514"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.issn","0007-1048"],["dc.title","Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1307"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1315"],["dc.bibliographiccitation.volume","90"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Sahlmann, Carsten Oliver"],["dc.contributor.author","Lakhani, Vijai J."],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T08:50:15Z"],["dc.date.available","2018-11-07T08:50:15Z"],["dc.date.issued","2011"],["dc.description.abstract","A phase II trial evaluated safety, feasibility and efficacy of a sequential tandem approach combining myeloablative BEAM chemotherapy and autologous stem cell transplantation (ASCT) with myeloablative radioimmunotherapy (HD-RIT), with I-131-anti-CD20 antibody (I-131-rituximab), followed by a second ASCT in patients with relapsed or refractory CD20+ B-cell lymphoma. According to protocol, 16 patients with relapsed (n=14) and refractory (n=2) CD20+ B-cell lymphoma received salvage therapy with rituximab and Dexa-BEAM, followed by BEAM (HD chemotherapy) and high-dose myeloablative radioimmunotherapy 2-6 months after BEAM. Nine of 16 patients received HD-RIT; seven patients were excluded before HD-RIT because of toxicity or progressive disease. Disease histologies were follicular lymphoma (FL) grades 1 and 2 (n=4), transformed follicular (FL 3b; n=6), diffuse large B-cell (DLBCL; n=4), mantle cell (n=1) and marginal zone lymphoma (n=1). After a median follow-up of 50.4 months for OS and 39.7 months for progression-free survival (PFS), estimated 4-year OS and PFS were 67% and 64%, respectively. The estimated 4-year OS and PFS for patients with FL were 80% and 78%, respectively. Toxicity was significant, including one fatal outcome due to pneumonitis. Tandem transplants consisting of HD chemotherapy followed by HD-RIT with I-131-coupled anti-CD20 are manageable and effective but toxic treatment modalities for relapsed poor prognosis CD20+ B-NHL."],["dc.identifier.doi","10.1007/s00277-011-1199-y"],["dc.identifier.isi","000296730300008"],["dc.identifier.pmid","21360108"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7836"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21653"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0939-5555"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with I-131-anti-CD20 antibody and stem cell rescue"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1031"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1038"],["dc.bibliographiccitation.volume","100"],["dc.contributor.author","Zettl, Florian"],["dc.contributor.author","Ziepert, Marita"],["dc.contributor.author","Altmann, Bettina"],["dc.contributor.author","Zeynalova, Samira"],["dc.contributor.author","Held, Gerhard"],["dc.contributor.author","Pöschel, Viola"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Wulf, Gerald G."],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Loeffler, Markus"],["dc.contributor.author","Trümper, Lorenz"],["dc.date.accessioned","2021-04-14T08:30:49Z"],["dc.date.available","2021-04-14T08:30:49Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00277-020-04345-3"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83385"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1432-0584"],["dc.relation.issn","0939-5555"],["dc.title","Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma—data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin’s Lymphoma Study Group)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","496"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Der Onkologe"],["dc.bibliographiccitation.lastpage","+"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Zettl, Florian"],["dc.contributor.author","Truemper, Lorenz H."],["dc.date.accessioned","2018-11-07T09:56:43Z"],["dc.date.available","2018-11-07T09:56:43Z"],["dc.date.issued","2015"],["dc.description.abstract","Aggressive lymphomas are more frequent in elderly patients and the median age at diagnosis is 64 years. Rational treatment decisions for elderly patients are difficult to make and often influenced by other factors, such as comorbidities and social status as well as experience and preferences of treating physicians. The results of published studies are summarized and discussed in this article. Recommendation for decision-making in this patient collective are presented. This article is based on a PubMed search using the terms aggressive lymphoma, elderly and therapy and on the evaluation of data from the German high-grade non-Hodgkin lymphoma study group. Even in elderly patients with aggressive lymphomas a combined immunochemotherapy including anthracyclines is the only curative treatment approach with a 5-year overall survival of approximately 75 % in fit elderly patients. The decision on whether such a regimen is feasible or a palliative life-extending concept should be selected, can only be made after a prephase therapy for individual patients. In addition, comorbidities and social factors, such as limitations in daily life activities must be incorporated into the treatment plan in this patient population. Geriatric assessments may aid the establishment of rational approaches. The final decision has to be made by the treating physician in close interaction with the patient and relatives."],["dc.identifier.doi","10.1007/s00761-014-2830-z"],["dc.identifier.isi","000355251500006"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37019"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1433-0415"],["dc.relation.issn","0947-8965"],["dc.title","Aggressive B cell lymphomas in elderly patients. Curative or palliative treatment strategy?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","949"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","British Journal of Haematology"],["dc.bibliographiccitation.lastpage","956"],["dc.bibliographiccitation.volume","184"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Windemuth-Kieselbach, Christiane"],["dc.contributor.author","Kolz, Julia"],["dc.contributor.author","Zinzani, Pier Luigi"],["dc.contributor.author","Cacchione, Roberto"],["dc.contributor.author","Jurczak, Woijciech"],["dc.contributor.author","Bischof Delaloye, Angelika"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Scholz, Christian W."],["dc.date.accessioned","2021-06-01T10:47:12Z"],["dc.date.available","2021-06-01T10:47:12Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1111/bjh.15712"],["dc.identifier.issn","0007-1048"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85516"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.issn","0007-1048"],["dc.title","Radioimmunotherapy (RIT) for Follicular Lymphoma achieves long term lymphoma control in first line and at relapse: 8-year follow-up data of 281 patients from the international RIT-registry"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Annals of Oncology"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Jung, Werner"],["dc.contributor.author","Stitz, E."],["dc.contributor.author","Meller, J."],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T10:18:39Z"],["dc.date.available","2018-11-07T10:18:39Z"],["dc.date.issued","2005"],["dc.format.extent","135"],["dc.identifier.isi","000233670100335"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41490"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.publisher.place","Oxford"],["dc.relation.conference","9th International Conference on Malignant Lymphoma"],["dc.relation.eventlocation","Lugano, SWITZERLAND"],["dc.relation.issn","0923-7534"],["dc.title","Tandem high dose chemotherapy and myeloablative radioimmunotherapy with 131-I-anti-CD20 rituximab in relapsed and refractory B-cell lymphoma: Interim results of a phase II study of the German RIT study group"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1585"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","European Journal of Nuclear Medicine and Molecular Imaging"],["dc.bibliographiccitation.lastpage","1592"],["dc.bibliographiccitation.volume","41"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Lankeit, Henrike Katharina"],["dc.contributor.author","Zinzani, Pier Luigi"],["dc.contributor.author","Scholz, C. W."],["dc.contributor.author","Lorsbach, Michael"],["dc.contributor.author","Windemuth-Kieselbach, C."],["dc.contributor.author","Truemper, Lorenz H."],["dc.date.accessioned","2018-11-07T09:37:21Z"],["dc.date.available","2018-11-07T09:37:21Z"],["dc.date.issued","2014"],["dc.description.abstract","Purpose Very few reliable clinical data about the use of radioimmunotherapy in aggressive B-cell lymphoma exist. Methods Patients with aggressive B-cell lymphoma registered in the international RIT-Network were analysed with regard to prior treatment, response and side effects. The RIT-Network is a web-based registry that collects observational data from radioimmunotherapy-treated patients with malignant lymphoma across 13 countries. Results This analysis included 215 with aggressive B-cell lymphoma out of 232 patients registered in the RIT-Network. Histological subtypes were as follows: 190 diffuse large B-cell, 15 primary mediastinal, 9 anaplastic large cell, and 1 intravascular lymphoma. The median age of the patients was 62 years (range 17 - 88), with 27 % above the age of 70 years. Radioimmunotherapy was mainly used as consolidation after first-line or second-line chemotherapy (56.1 %), as part of third-line to eighth-line therapy for relapse (16.4 %), and in refractory disease (12.2 %). Grade IV neutropenia and thrombopenia and grade III anaemia were observed. The median time to recovery of blood count was 81 days (range 0 - 600 days). The overall response rate was 63.3 %. The complete response rate was 76.4 % in patients treated as part of first-line therapy, and 44.3 % in patients with relapse. Mean overall survival in first-line therapy patients was 32.7 months and 14.0 months in patients with relapse or refractory disease, respectively. Conclusion Most patients with aggressive B-cell lymphoma in the RIT-Network received radioimmunotherapy as consolidation after first-line therapy with excellent complete remission and overall survival rates compared to published data. In relapsed aggressive B-cell lymphoma, radioimmunotherapy is a safe and feasible treatment leading to satisfactory response rates with acceptable toxicity."],["dc.description.sponsorship","Bayer Healthcare"],["dc.identifier.doi","10.1007/s00259-014-2758-y"],["dc.identifier.isi","000339334000014"],["dc.identifier.pmid","24722703"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32822"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1619-7089"],["dc.relation.issn","1619-7070"],["dc.title","Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1073"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1079"],["dc.bibliographiccitation.volume","99"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Windemuth-Kieselbach, Christine"],["dc.contributor.author","Zinzani, Pier Luigi"],["dc.contributor.author","Cacchione, Roberto"],["dc.contributor.author","Jurczak, Wojciech"],["dc.contributor.author","Suh, C."],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Scholz, Christian W."],["dc.date.accessioned","2020-12-10T14:10:06Z"],["dc.date.available","2020-12-10T14:10:06Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00277-020-03956-0"],["dc.identifier.eissn","1432-0584"],["dc.identifier.issn","0939-5555"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70648"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","181"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","eJHaem"],["dc.bibliographiccitation.lastpage","187"],["dc.bibliographiccitation.volume","1"],["dc.contributor.author","Høhloch, Karin"],["dc.contributor.author","Ziepert, Marita"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Buske, Christian"],["dc.contributor.author","Held, Gerhard"],["dc.contributor.author","Poeschel, Viola"],["dc.contributor.author","Chapuy, Björn"],["dc.contributor.author","Altmann, Bettina"],["dc.date.accessioned","2020-12-11T11:48:55Z"],["dc.date.accessioned","2021-10-27T13:22:25Z"],["dc.date.available","2020-12-11T11:48:55Z"],["dc.date.available","2021-10-27T13:22:25Z"],["dc.date.issued","2020"],["dc.description.abstract","Serum albumin a well‐known risk factor predicting outcome in many solid tumors. We explore the role of low serum albumin (≤3.5 g/dL) as an independent risk factor in elderly patients with aggressive B‐cell lymphoma. Outcome of 429 patients treated with R‐CHOP‐14 in the RICOVER‐60 trial and available serum albumin were analyzed in this retrospective study. Of the 429 patients in the RICOVER‐60 trial, 137 (32%) had low and 292 (68%) had normal serum albumin levels (>3.5 g/dL). In the low albumin group, patients had significantly higher International Prognostic Index (IPI), bulky disease, extralymphatic involvement, and B‐symptoms. Event‐free survival (EFS) (P < .001), progression‐free survival (PFS) (P < .001), and overall survival (OS) (P < .001) were significantly inferior for patients with low compared to those with normal serum albumin. Multivariate analysis adjusted for IPI shows following Hazard ratios (HR) for low serum albumin: EFS (HR = 1.5; 95% confidance interval [CI] [1.1; 2.1], P = .009), PFS (HR = 1.7; 95% CI [1.2; 2.4], P = .001) and OS (HR = 1.6; 95% CI [1.1; 2.3], P = .006). Results were confirmed in 185 patients from the DENSE‐R‐CHOP‐14 and SMARTE‐R‐CHOP‐14 trials. In conclusion, low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma treated with R‐CHOP."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2020"],["dc.identifier.doi","10.1002/jha2.61"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17695"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92093"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.eissn","2688-6146"],["dc.relation.issn","2688-6146"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma: Results from prospective trials of the German High‐Grade Non‐Hodgkin's Lymphoma Study Group"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]